Edition:
United States

Alere Inc (ALR.N)

ALR.N on New York Stock Exchange

50.50USD
4:02pm EDT
Change (% chg)

$0.04 (+0.08%)
Prev Close
$50.46
Open
$50.46
Day's High
$50.53
Day's Low
$50.40
Volume
426,189
Avg. Vol
248,500
52-wk High
$50.58
52-wk Low
$34.41

Latest Key Developments (Source: Significant Developments)

Abbott announces extension of cash tender offer
Monday, 18 Sep 2017 08:01am EDT 

Sept 18 (Reuters) - Abbott Laboratories :Abbott announces extension of cash tender offer for all outstanding shares of series B convertible perpetual preferred stock of Alere Inc..Abbott Laboratories - ‍ offer will now expire at 11:59 p.m., New York City time, on Friday, Sept. 29, 2017​.  Full Article

Quidel announces revised agreement for pending acquisition of Alere’s business
Monday, 18 Sep 2017 07:00am EDT 

Sept 18 (Reuters) - Quidel Corp :Quidel announces revised agreement for its pending acquisition of Alere’s B-type Naturietic Peptide (BNP) assay business run on Beckman Coulter Analyzers.Quidel - ‍ previously announced transaction to purchase Triage Meterpro cardiovascular and toxicology assets from alere remains substantially unchanged​.Quidel-‍revised agreement provides co direct commercial responsibility after purchase for all sales globally of Alere's BNP assay unit run on Beckman Analyzers​.Quidel Corp - ‍ transactions will be funded through a combination of cash on hand and committed financing​.Quidel Corp - ‍total cash consideration for Alere's Triage MeterPro assets and beckman coulter bnp sales​ will now be up to $680 million.Quidel Corp - ‍ believe co is on track to close acquisition of Triage and BNP businesses within 30 days of Abbott's close of Alere acquisition​.Quidel- deal consideration of $680 million made of $400 million purchase price for triage business, $40 million in contingent consideration for eea bnp business.Quidel- deal consideration of $680 million also comprised of $240 million in deferred consideration for rest-of-world BNP business​.  Full Article

Abbott extends cash tender offer for all outstanding shares of series B convertible perpetual preferred stock of Alere
Friday, 1 Sep 2017 08:00am EDT 

Sept 1 (Reuters) - Abbott Laboratories :Abbott announces extension of cash tender offer for all outstanding shares of series B convertible perpetual preferred stock of Alere .‍Offer is being extended to allow additional time for consummation of merger, which is a condition to completion of offer​.‍Extending tender offer to buy for cash all outstanding shares of preferred stock of alere at price of $402.00/share of preferred stock​.‍Offer will now expire at 11:59 p.m., New York City time, on Friday, Sept. 15, 2017​.  Full Article

Abbott says commences tender offer for Series B preferred stock of Alere
Monday, 17 Jul 2017 08:18am EDT 

July 17 (Reuters) - Abbott Laboratories :Abbott commences cash tender offer for all outstanding shares of series b convertible perpetual preferred stock of Alere Inc.Abbott Laboratories - tender offer to buy all outstanding series b convertible perpetual preferred stock of alere at $402.00/share of preferred stock​.Abbott Laboratories - ‍offer will expire at 11:59 P.M., New York City time, on Friday, August 11, 2017​.  Full Article

Quidel announces definitive agreement to acquire Alere Triage assets
Monday, 17 Jul 2017 06:00am EDT 

July 17 (Reuters) - Quidel Corp :Quidel Corp - ‍accretive transactions extend Quidel's market leadership and position it for future growth​.Quidel Corp- ‍transactions will be funded through a combination of cash on hand and committed financing​.Quidel Corp - to buy Triage business and B-type Naturietic Peptide (BNP) business for a total consideration of $400 million plus $40 million in contingent consideration​.Quidel Corp - ‍transactions are to be financed with cash plus committed financing from Bank of America Merrill Lynch and J.P. Morgan Chase Bank.Quidel Corp - ‍Quidel will distribute Triage MeterPro products and BNP assays through a combination of direct sales force and distributors​.  Full Article

Alere shareholders approve amended merger with Abbott
Friday, 7 Jul 2017 04:15pm EDT 

July 7 (Reuters) - Alere Inc :Alere shareholders approve amended merger with abbott.Alere says about 63 million of votes cast at special meeting voted in favor of amended merger, representing over 72.5 percent of alere shares as of may 31.  Full Article

Alere declares dividend of $3.00/shr on Series B convertible perpetual preferred stock
Friday, 23 Jun 2017 04:15pm EDT 

June 23 (Reuters) - Alere Inc :Alere Inc - declared a cash dividend of $3.00 per share on its Series B convertible perpetual preferred stock.  Full Article

Alere Q1 loss per share $0.80 from continuing operations
Wednesday, 14 Jun 2017 04:15pm EDT 

June 14 (Reuters) - Alere Inc ::Alere reports first quarter 2017 financial results.Q1 gaap loss per share $0.80 from continuing operations.Q1 revenue $588 million versus I/B/E/S view $592.3 million.Q1 earnings per share view $0.48 -- Thomson Reuters I/B/E/S.Alere Inc - on june 8, coinformed by U.S. DOJ that it is closing investigation of operations at co's pain management laboratory in austin, texas.Q1 2017 results reflect strong u.s. Sales growth driven by influenza and respiratory sales.Alere - non-gaap adjusted ebitda was $68 million in q1 of 2017, a 40 pct decrease compared to $113 million in prior year period.Alere - informed by U.S. DOJ that it is closing investigation without taking any action against company.  Full Article

Alere reports termination of consent solicitations for notes
Monday, 5 Jun 2017 04:55pm EDT 

June 5 (Reuters) - Alere Inc ::Alere Inc. announces termination of consent solicitations for Alere's notes and offers consent termination fee.Alere - ‍termination of previously announced consent solicitations relating to company's 6.500 pct senior subordinated notes due 2020​.Alere-‍termination of previously announced consent solicitations also relating to 6.375 pct senior subordinated notes due 2023 and 7.250 pct senior notes due 2018​.  Full Article

Alere Q4 loss per share $1.38 from continuing operations
Monday, 5 Jun 2017 04:39pm EDT 

June 5 (Reuters) - Alere Inc ::Alere files form 10-k, reports fourth quarter and full year 2016 financial results.Q4 gaap loss per share $1.38 from continuing operations.Q4 revenue $597 million versus I/B/E/S view $607.4 million.Q4 earnings per share view $0.50 -- Thomson Reuters I/B/E/S.Alere Inc - ‍abbott transaction is expected to close by end of q3 of 2017​.Alere Inc - ‍due to pending transaction with Abbott, Alere will no longer hold conference calls to discuss its quarterly financial results​.  Full Article

BRIEF-Alere announces intent to voluntarily delist Series B Convertible Perpetual Preferred Stock from the NYSE

* Alere announces intent to voluntarily delist Series B Convertible Perpetual Preferred Stock from the NYSE conditioned upon the completion of its acquisition by Abbott